Dr. Lawrence N. Gray has earned a great deal of respect in the national plastic surgical community through his many publications, technical skill and personal demeanor. Dr Gray and his staff have been recognized by a national survey as having one of the highest levels of customer service.

Dr. Gray performs 4 times the national average of breast augmentation and is routinely invited to teach courses and participate in panel discussions at ASPS and ASAPS meetings. He has been chosen 2 years in a row as one of 25 plastic surgeons in the United States to participate in the Mentor "Lead" program. Dr. Gray has received the significant honor of being selected as one of only 15 plastic surgeons in the country chosen to participate in a Silicone Clinical Trial and approved to use silicone implants.

Dr. Gray is also the Originator of the Scarless Breast Reduction procedure. He has performed more than 900 cases of this liposuction breast reduction, has published extensively and regularly teaches this method to other plastic surgeons at national conferences. Most recently, Dr. Gray has been selected to have his patients be part of a new Clinical research study. Dr Gray attended training in Las Vegas, Nevada for an FDA trial of Mentor adjustable silicone implants, the first adjustable silicone implant to be brought to the market.  Dr. Gray was one of 30 plastic surgeons selected across the entire United States to participate. Selection of the surgeons was based on national reputation, certification of the surgeon's facility and previous participation in 6 other previous trials: 2 with Mentor, 2 with Allergan and 2 with Silimed corporations. This implant offers better control for breast symmetry and the implant size can be adjusted for up to 6 months after surgery. Participants will be paid $2200 for their involvement. Implants are guaranteed and patients will have MRIs to check implant integrity at no cost to the patient. Dr. Gray has 10 patient spots available for the core study. Patients who are interested should contact as soon as possible. There may be additional patient slots for a continued access study at a later time.